Cormorant Asset Management’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Cormorant Asset Management’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,226,961	Closed	-$221K	–	91
2016 Q3	$221K	Hold	2,226,961	–	–	0.02%	78
2016 Q2	$824K	Buy	2,226,961 +26,961	+1%	+$10.3K	0.12%	71
2016 Q1	$836K	Hold	2,200,000	–	–	0.13%	72
2015 Q4	$858K	Hold	2,200,000	–	–	0.1%	71
2015 Q3	$1.26M	Hold	2,200,000	–	–	0.2%	68
2015 Q2	$1.19M	Buy	+2,200,000	New	+$1.79M	0.16%	69

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Cormorant Asset Management's PVCT Position: Q4 2016 in Review

Cormorant Asset Management sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 2,226,961 shares — an estimated $221K sold.

Cormorant Asset Management first reported a position in PVCT in Q2 2015 and held it in 6 quarters. The position peaked at $1.26M in Q3 2015. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

Cormorant Asset Management reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
Cormorant Asset Management sold 2,226,961 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $221K.
Cormorant Asset Management first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q2 2015 and held it in 6 quarters.
Cormorant Asset Management's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $1.26M in Q3 2015.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.